• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable i

tetano

Editor, Senior Moderator
Vaccine


. 2025 Sep 12:127677.
doi: 10.1016/j.vaccine.2025.127677. Online ahead of print. High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons

Aaron Lane[SUP] 1 [/SUP], Huy Q Quach[SUP] 2 [/SUP], Inna G Ovsyannikova[SUP] 2 [/SUP], Richard B Kennedy[SUP] 2 [/SUP], Ted M Ross[SUP] 3 [/SUP], Tal Einav[SUP] 4 [/SUP]



Affiliations
Abstract

Most influenza vaccine studies evaluate acute antibody responses 1 month post-vaccination, yet the finer details of immune kinetics remain poorly understood. Here, we conducted two new vaccine studies and analyzed 12 prior vaccine studies to map antibody responses against H3N2 and H1N1 influenza in high resolution from the day of vaccine administration out to 1 year post-vaccination. Antibody kinetics corresponded to three major phenotypes, namely, weak (<4x fold-change at 1 month and 1 year), transient (≥4x at 1 month, <4x at 1 year), or durable (≥4x at 1 month and 1 year). Surprisingly, ≥50 % of vaccine recipients were weak across nearly all seasons, age groups, sexes, pre-vaccination titers, and high or standard vaccine doses examined. Peak fold-change at 1 month post-vaccination was strongly associated with the long-term response, with transient responders often achieving a peak fold-change of 4x and then decaying back to baseline, while durable responders reached ≥16x fold-change and maintained comparable titers out to 1 year. Using the weak, transient, and durable trajectories, a single time point early in the response (days 7-8 or 21) predicted an individual's response out to 1 year post-vaccination. These results highlight the stark heterogeneity that is consistently seen across influenza seasons, where the vaccine elicits little-to-no response in some but strong and long-lasting antibody immunity in others.

Keywords: Antibody response; Hemagglutination inhibition; Influenza; Predictive modeling; Time dynamics; Vaccination; Vaccine durability; Vaccine waning.

 
Back
Top Bottom